RIPK3 and acute lymphoblastic leukemia: Most (77%, 17/22) of the Ripk3−/− mice developed acute T lymphoblastic leukemia (T-ALL) and died within 200 days, while the remaining Ripk3−/− mice developed a mixture of T-ALL/thymoma and died within 250 days (Figure 3A).